

Low-Dose Aspirin-Induced Upper Gastrointestinal Injury-Epidemiology, Management and Prevention

Tzung-Jiun Tsai^{1,2} and Ping-I Hsu^{1,2*}

¹Department of Internal Medicine, Division of Gastroenterology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

²National Yang-Ming University, Taipei, Taiwan

*Corresponding author: Ping-I Hsu, Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, 386 Ta Chung 1st Road, Kaohsiung 813, Taiwan, Tel: +886-7-3468233; Fax: +886-7-3468237; E-mail: williamhsup@yahoo.com.tw

Received date: Nov 17, 2015, Accepted date: Dec 21, 2015, Publication date: Dec 26, 2015

Copyright: © 2015 Tsai TJ, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Low-dose aspirin, defined as 75-325 mg daily, is widely used for the primary and secondary prevention of cardiovascular (CV) events. Currently, approximately 36% of the adult US population more than 50 million people are estimated to take aspirin regularly for CV protection [1]. The low-dose aspirin use may induce a wide range of adverse side effects in the upper gastrointestinal (GI) tract, which range from troublesome symptoms to life-threatening peptic ulcer bleeding, perforation [2] and even death [3].

Both upper GI symptoms and gastroduodenal erosions are very common in low-dose aspirin users. The point prevalence rates of upper GI symptoms and gastroduodenal erosions in low-dose aspirin users are approximately 31% and 60%, respectively [4,5]. Most of low-dose aspirin-related peptic ulcers are asymptomatic. A multi-nation trial revealed that only 20% of low-dose aspirin related peptic ulcers were associated with dyspeptic symptoms [4]. A prospective study demonstrated that the 12-week cumulative incidence of endoscopic ulcers in low-dose aspirin users was 7% [6]. The annual incidence of major GI bleeding in patients receiving low-dose aspirin therapy ranges from 0.07% to 1.57% [7-10].

Low-dose aspirin users who develop an acute peptic ulcer bleeding event represent a serious challenge for physicians. Withdrawal of low-dose aspirin in the subjects taking low-dose aspirin for CV protection is associated with a threefold increase in the CV event risk [11]. A randomized, placebo-controlled trial [12] also disclosed that bleeding ulcer patients who stopped taking aspirin treatment after endoscopic hemostasis therapy had a higher 56-day all-cause mortality rate than those who kept taking aspirin (12.9 vs 1.3%). However, the former had an insignificantly lower rebleeding rate than the latter (5.4% vs 10.3%). The physicians therefore should balance the risks of CV events and rebleeding in the management of low-dose aspirin-related peptic ulcer bleeding. In general, stopping antiplatelet therapy during acute ulcer bleeding in patients taking low-dose aspirin for primary prevention of CV events is reasonable. In contrast, early resumption of antiplatelet agent with a proton pump inhibitor (PPI) in bleeding ulcer patients who take aspirin for secondary CV protection is strongly recommended [12].

It is still unclear when is the best timing for re-starting low-dose aspirin therapy in low-dose aspirin users with acute ulcer bleeding. Several prospective studies showed that most of the rebleeding events in patients with peptic ulcer bleeding occurred in the first 3 days of admission [13]. Theoretically, aspirin can permanently inactivate the COX activity of platelets, and the antiplatelet effects of aspirin may last for a few days after cessation of aspirin. A prospective study by

Komatsu et al. documented that the bleeding time returned to normal values at 3 days following discontinuation of aspirin in healthy subjects [14]. A cohort study [15] showed that most events of strokes related to discontinuation of antiplatelet agents occurred between 6 and 10 days following cessation of antiplatelet agents. Therefore, resuming antiplatelet agents at 3-5 days after the last dosing of aspirin is a reasonable strategy in the treatment of bleeding ulcer patients who take aspirin for secondary prevention of CV diseases and have high-risk bleeding stigmata at initial endoscopy [16]. Nonetheless, bleeding ulcer patients with clean-base ulcers at initial endoscopy can continue antiplatelet therapy immediately following endoscopic assessment.

In the management of uncomplicated peptic ulcers for low-dose aspirin users, the physicians should also balance the risks of GI injury and benefits of CV protection of antiplatelet therapy. Early resuming antiplatelet agents is indicated for patients with previous CV events. Besides those taking aspirin for secondary CV protection, the American Heart Association also recommends prophylactic aspirin to the subjects with a 10-year CV risk 10% [17]. The 10-year CV risk of an individual subject can be assessed by the Framingham calculator (website: <http://hin.nhlbi.nih.gov/atpii/calculator.asp?usertype=prof>). A recent study by Liu et al. demonstrated that there were no differences in the ulcer healing rates between ulcer patients receiving PPI-plus-aspirin and PPI alone therapies [18]. Therefore, prescribing a powerful PPI with continuation of aspirin is recommended in the treatment of uncomplicated peptic ulcer for patients who require low-dose aspirin therapy.

For the long-term prevention of recurrent ulcers, patients with a history of complicated or non-complicated peptic ulcer history who require low-dose aspirin therapy for CV protection should be tested for the presence of *H pylori* infection [19]. Eradication therapy is indicated for those with *H pylori* infection. Additionally, patients should also be assessed for other risk factors for peptic ulcers and GI bleeding such as concomitant use of NSAID or anticoagulant. Co-therapy with an antisecretory agent, preferably a PPI, is recommended for those with a high risk for ulcer complications [20]. Several randomized, control trials [20] demonstrated that co-therapy with PPI significantly reduced the rate of recurrent bleeding in low-dose aspirin users with prior histories of bleeding ulcers. Though H₂ receptor antagonist can reduce the risk of upper GI bleeding in low-dose aspirin users, it is inferior to PPI in preventing recurrence of aspirin-related peptic ulcers or erosions [21].

In conclusion, low-dose aspirin therapy is associated with upper GI side effects ranging from dyspepsia, gastroduodenal erosions, and asymptomatic endoscopic ulcers to complicated peptic ulcers. Early resumption of antiplatelet agent with co-therapy of a PPI is strongly

recommended in the management of bleeding ulcer patients who take aspirin for secondary CV protection and have high-risk bleeding stigmata at initial endoscopy. The optimal timing to restart antiplatelet agents in bleeding ulcer patients who undergo antiplatelet therapy remains unclear but resuming low-dose aspirin at 3-5 days after the last dosing is a reasonable strategy. In the treatment of low-dose aspirin-related uncomplicated of peptic ulcers, continuing aspirin plus a powerful PPI is recommended for those requiring antiplatelet therapy. For the prevention of recurrent peptic ulcers and ulcer complications, eradication therapy is indicated for *H pylori* infected aspirin users who have an ulcer history. Additionally, co-therapy with a PPI is recommended for those with a high risk of ulcer complications.

References

1. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH (2006) Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. *Am J Prev Med* 30: 74-77.
2. Taha AS, Angerson WJ, Prasad R, McCloskey C, Gilmour D, et al. (2008) Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. *Aliment Pharmacol Ther* 28: 878-885.
3. Lanas A (2011) Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. *Expert Opin Drug Saf* 10: 45-54.
4. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, et al. (2005) Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. *Aliment Pharmacol Ther* 22: 795-801.
5. Simon B, Elsnér H, Müller P (1995) [Protective effect of omeprazole against low-dose acetylsalicylic acid. Endoscopic controlled double-blind study in healthy subjects]. *Arzneimittelforschung* 45: 701-703.
6. Laine L, Maller ES, Yu C, Quan H, Simon T (2004) Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. *Gastroenterology* 127: 395-402.
7. Medical Research Council's General Practice Research Frame Work (1988) Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. *Lancet* 351: 233-241.
8. [No authors listed] (1989) Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. *N Engl J Med* 321: 129-135.
9. Gavaghan TP, GebSKI V, Baron DW (1991) Immediate postoperative aspirin improves vein graft patency early and late after coronary artery bypass graft surgery. A placebo-controlled, randomized study. *Circulation* 83: 1526-1533.
10. Hsu PI, Tsai TJ (2015) Epidemiology of Upper Gastrointestinal Damage Associated with Low-Dose Aspirin. *Curr Pharm Des* 21: 5049-5055.
11. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, et al. (2006) A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. *Eur Heart J* 27: 2667-2674.
12. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, et al. (2010) Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. *Ann Intern Med* 152: 1-9.
13. Hsu PI, Lai KH, Lin XZ, Yang YF, Lin M, et al. (1996) When to discharge patients with bleeding peptic ulcers: a prospective study of residual risk of rebleeding. *Gastrointest Endosc* 44: 382-387.
14. Komatsu T, Tamai Y, Takami H, Yamagata K, Fukuda S, et al. (2005) Study for determination of the optimal cessation period of therapy with antiplatelet agents prior to invasive endoscopic procedures. *J Gastroenterol* 40: 698-707.
15. Sibon I, Orgogozo JM (2004) Antiplatelet drug discontinuation is a risk factor for ischemic stroke. *Neurology* 62: 1187-1189.
16. Hsu PI (2012) New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment. *J Gastroenterol Hepatol* 27: 654-661.
17. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, et al. (2002) AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. *Circulation* 106: 388-391.
18. Liu CP, Chen WC, Lai KH, Mar GY, Lin SY, et al. (2012) Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. *Am J Gastroenterol* 107: 1022-1029.
19. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, et al. (2009) Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. *J Gastroenterol Hepatol* 24: 1587-1600.
20. Lai KC, Lam SK, Chu KM, Wong BC, Hui WM, et al. (2002) Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. *N Engl J Med* 346: 2033-2038.
21. Ng FH, Wong SY, Lam KF, Chu WM, Chan P, et al. (2010) Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. *Gastroenterology* 138: 82-88.